


1 mag 2

1635

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. UCT-0012-P
In Re Application Of: HLA, et al.			
Serial No. 09/945,353	Filing Date August 31, 2001	Examiner M. Schmidt	Group Art Unit 1635
Title: METHOD FOR REGULATING ANGIOGENESIS			
<div style="display: flex; justify-content: space-around; align-items: center;"><div style="text-align: center;"></div><div style="text-align: center;"><p>Address to:</p><p>Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</p><p>37 CFR 1.97(b)</p><p>1. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p><p style="text-align: center;">37 CFR 1.97(c)</p><p>2. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p><div style="margin-left: 40px;"><p><input checked="" type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p><p style="text-align: center;">OR</p><p><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p></div></div></div>			

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
UCT-0012-P

In Re Application: HLA, et al.


Serial No.
09/945,353

Filing Date
August 31, 2001

Examiner
M. Schmidt

Group Art Unit
1635

METHOD FOR REGULATING ANGIOGENESIS



Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 06-1130 as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on 09-16-2003 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Marjorie R. Humes

Signature of Person Mailing Correspondence

Marjorie R. Humes

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Karen A. LeCuyer

Signature

Dated: September 16, 2003

Karen A. LeCuyer
Registration No. 51,928
Telephone: (860) 286-2929

CC:

**STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

Docket No.
UCT-0012-P

In Re Application Of: HLA, et al.


Serial No.
09/945,353

Filing Date
August 31, 2001

Examiner
M. Schmidt

Group Art Unit
1635

Invention: METHOD FOR REGULATING ANGIOGENESIS



TO THE COMMISSIONER FOR PATENTS:

This is a statement under the provisions of 37 CFR 1.97(e) in the above-identified application.

Check applicable statement herebelow:

Statement Under 37 CFR 1.97(e)(1)

- ☒ Each item of information contained in the accompanying Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

Statement Under 37 CFR 1.97(e)(2)

- ☐ No item of information contained in the accompanying Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned person, after making reasonable inquiry, no item of information contained in the accompanying Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Karen A. LeCuyer
Signature

Dated: September 16, 2003

Karen A. LeCuyer
Registration No. 51,928
Telephone: (860) 286-2929

Certificate of Mailing by First Class Mail

I certify that this document is being deposited on
September 16, 2003 with the U.S. Postal Service as first
class mail under 37 C.F.R. 1.8 and is addressed to the
Commissioner for Patents, P.O. Box 1450, Alexandria, VA
22313-1450.

Marjorie R. Humes

Signature of Person Mailing Correspondence

Marjorie R. Humes

Typed or Printed Name of Person Mailing Correspondence

CC:

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): HAL, et. al.

Docket No.

UCT-0012-P

Serial No.

09/945,353

Filing Date

August 31, 2001

Examiner

m. sCHMIDT

Group Art Unit

1635

Invention: **METHOD FOR REGULATING ANGIOGENESIS**

I hereby certify that this Transmittal of Information Disclosure Statement; Statement; 1449; cited reference
(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 16, 2003

(Date)

Marjorie R. Humes

(Typed or Printed Name of Person Mailing Correspondence)


Marjorie R. Humes

(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

UCT-0012-P

Application Number

09/945,353

Applicant(s)

HAL, et al.

Filing Date

August 31, 2001

Group Art Unit

1635

*EXAMINER
INITIAL

OTHER DOCUMENTS

(Indicate Author, Title, Date, Pertinent Pages, Etc.)

Wang, Fang et al: "Sphingosine 1-phosphate stimulates cell migration through a Gi-coupled cell surface receptor. Potential involvement in angiogenesis"; Journal of Biological Chemistry (1999), 274(50), 35343-35350, XP002244343 Abstract.

Okamoto, H. et al: "Sphingosine 1-Phosphate Stimulates Gi- and Rho-Mediated Vascular Endothelial Cell Spreading and Migration"; Thrombosis Research (2000), 99(3), 259-265; XP002244344 abstract.

English, Denis et al.: "Induction of endothelial cell chemotaxis by sphingosine 1-phosphate and stabilization of endothelial monolayer barrier function by lysophosphatidic acid, potential mediators of hematopoietic angiogenesis"; Journal of Hematotherapy & Stem Cell Research (1999), 8(6), 627-634, XP008018336 abstract.

Lee, Menq-Jer et al: "Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate" CELL (Cambridge, Massachusetts) (1999), XP002244485 abstract.

Nakajima N et al: "Expression and characterization of Edg-1 receptors in rat cardiomyocytes: calcium deregulation in response to sphingosine 1-phosphate." European Journal of Biochemistry / Febs. Germany Sep. 2000, vol. 267, no. 18, September 2000 (2000-09), pages 5679-5686, XP002250815 ISSN: 0014-2956 abstract.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.